Immunovant (NASDAQ:IMVT) PT Raised to $51.00 at Bank of America
Immunovant (NASDAQ:IMVT – Free Report) had its target price upped by Bank of America from $49.00 to $51.00 in a report released on Thursday morning, Benzinga reports. Bank of America currently has a buy rating on the stock. IMVT has been the subject of several other reports. Raymond James upgraded shares of Immunovant from a […]
More Stories
Democrats Sue Trump Admin Over Bid to Clean Up Voter Rolls
By Zachary Stieber Senate Minority Leader Chuck Schumer (D-N.Y.) and other Democrats have sued the Trump administration over its effort...
Implementing Freight Management Software: In-House or With Specialist Help?
You’ve picked a freight platform. Now you have to get it live without stopping trucks, missing invoices or losing track...
DOGE Illegally Accessed Data on Government Workers: Judge
By Zachary Stieber A federal judge ruled on Oct. 20 that a department aimed at making the government more efficient...
UK Rearrests 2 Men Over Suspected Terror Plot at Air Base
By Jill McLaughlin UK police have rearrested two men, suspected of working for Iran’s intelligence service, for allegedly plotting to...
$245 Million Taxpayer-Backed Loan to Fund Naval Shipbuilding Facilities
By AAP Australia will lend hundreds of millions of dollars to the nation’s largest shipbuilder for a massive new manufacturing...
Music Publishers Sue Anthropic for Copyright Infringement
By Stacy Robinson A federal district court in California is set to hear arguments this week as a group of...